Anagrelide is an imidazoquinazoline anti-platelet compound that inhibits platelet aggregation at high doses and decreases platelet activity at low doses. Anagrelide inhibits phosphodiesterase III (PDE3). Anagrelide also decreases expression of GATA-1 and FOG1, suppressing megakaryocytopoiesis; it shows benefit in the treatment of chronic myeloproliferative disorders such as thrombocythemia. In vitro, anagrelide inhibits thrombopoietin-mediated cell differentiation.

References


